 NEW YORK, Nov. 17, 2020 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS, a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, today announced that the U.S. Food and Drug Administration FDA has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma MM. 